A Phase I Clinical Study of Safety, Tolerability, and Pharmacokinetics / Pharmacodynamics of Single and Multiple Ascending Doses of PSTB100 Tablets in Healthy Adult Subjects

Prospect Therapeutics (Nanjing) Limited2 个研究点分布在 1 个国家目标入组 68 人开始时间: 2026年7月14日最近更新: 2026年9月4日

适应症

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 68
试验地点: 2
主要终点: Time to Reach Maximum Observed Plasma concentration (Tmax)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a randomized, double-blind, placebo-controlled, dose-escalation， first-in-human clinical trial in healthy adults, designed to assess the safety, tolerability, and PK characteristics of PSTB100 tablets.

详细描述

This Phase I clinical trial is a randomized, double-blind, placebo-controlled, dose-escalation study consisting of two parts:

Part1: Single Ascending Dose (SAD) study Part2: Multiple Ascending Dose (MAD) study The SAD part uses a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, and PK/PD profile of single oral doses of PSTB100 Tablets under fasting conditions in healthy adult subjects.

The MAD part uses a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, and PK/PD profile of multiple oral doses of PSTB100 Tablets in healthy adults.

In addition, one dose cohort (expected to be Cohort 8) will include assessments of PK/PD changes of PSTB100 in cerebrospinal fluid (CSF) after repeated dosing.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•1.Healthy subjects aged 18-55 years (inclusive) at screening, with no gender restriction.
•Cohort 8 will enroll only male subjects aged 18-45 years (inclusive) at screening.
•2.Body Mass Index (BMI) of 18.0 to 32.0 kg/m² (inclusive), and 19.0 to 26.0 kg/m² (inclusive) for Cohort
•3.Good health status confirmed by medical history, vital signs, physical examination, 12-lead ECG, laboratory tests (blood routine, biochemistry, coagulation function, urinalysis), etc., with no clinically significant abnormalities.
•4.Fully informed about the study, voluntary participation, and signed Informed Consent Form (ICF).
•5. Women of childbearing potential who have no pregnancy plan from the screening period until 1 month after the end of the trial, and agree to use contraceptive methods as detailed further in the protocol (see Appendix 3) from signing the ICF until 30 days after last dose.
•6.Males who agree to use contraception as detailed further in the protocol (see Appendix 3) with partners of childbearing potential from signing ICF until 90 days after last dose.

排除标准

•1.Females who are pregnant (positive or clinically abnormal pregnancy test result), lactating, or planning to become pregnant.
•2.Pulse rate ≤50 beats/min or >100 beats/min at screening.
•3.Systolic blood pressure <90 mmHg or ≥140 mmHg, or diastolic blood pressure <60 mmHg or ≥90 mmHg at screening.
•4.History or current presence of clinically significant diseases or abnormalities in cardiovascular, respiratory, digestive, endocrine, metabolic, neurological, dermatological, ophthalmological, infectious, or psychiatric systems, including but not limited to history of eczema, no use of steroid creams for 3 months prior to screening; current or history of attention deficit hyperactivity disorder (ADHD), anxiety or depression (no use of antidepressants for at least 6 months prior to screening); Gilberts syndrome.
•Subjects with previous non-severe diseases or cured acute diseases may be enrolled if the assessor confirms no impact on the clinical trial.
•5.Use of tobacco, coffee, St. John's wort, grapefruit, grapefruit juice, cranberry juice, or strenuous exercise within 24 hours before enrollment.
•6.6.Suspected or confirmed allergy to any ingredient of the investigational product, or any known allergy history (however, subjects with mild allergies such as to pollen, cats or dust, which is fully resolved or without any treatment for more than 3 years can be enrolled).
•7.Previous surgery that may affect the clinical trial results (including but not limited to cholecystectomy, subtotal gastrectomy; excluding minor surgeries such as subcutaneous lipoma resection).
•8.Use of any medication within 14 days before the study drug administration, including over-the-counter drugs and herbal medicines (except vitamins and calcium tablets), or dietary supplement within 7 days before the study drug administration.
•9.Blood loss or blood donation exceeding 400 mL within 30 days before screening (physiological blood loss excluded).
•10.Participation in any clinical trial of investigational drugs or medical devices within 3 months (or within 5 half-lives of investigational drugs, whichever is longer) before screening (excluding subjects who failed screening).
•11.History of alcohol abuse. Subjects who consumed more than 14 standard alcohol units weekly within the past year (1 standard unit ≈ 250 mL of 5% beer; 100 mL of 12.5% wine; 30 mL of 42% spirits) or who refuse to abstain from alcohol during the trial.
•12.History of smoking abuse (average ≥ 5 cigarettes daily within 1 month before screening) or refusal to abstain from smoking during the trial.
•13.History of drug abuse or positive urine drug screening result during screening (subjects with positive cotinine at screening [D-28~D-2] will be not excluded if a negative cotinine is obtained on D-1).
•14.Breath alcohol test with positive result at screening.
•15.Clinically abnormal results of HBsAg, anti-HBcAb, anti-TP (if applicable), anti-HCV, anti-HIV, or QuantiFERON Gold.
•16.History of severe/serious bacterial infection, recurrent (>3× per year) bacterial infections, or herpes simplex virus (HSV) infection.
•17.Subjects who received live vaccine within 4 weeks of screening, or plan to receive live vaccine during and up to 4 weeks after the last dose of investigational product.
•18.Subjects for Cohort 8 will be excluded if:
•Experienced cold, infection, etc., within 4 weeks before screening.
•Have contraindications or are unsuitable for lumbar puncture.
•19. Any other situation that the researcher considers may bring safety risks to the subject, interfere with the study, or that the subject may not complete the study or comply with the requirements (due to management reasons, dysphagia, or other reasons).

研究组 & 干预措施

A MAD study with randomized, double-blind, placebo-controlled

Experimental

The MAD study includes 3 predefined dose cohorts (Cohorts 6-8)， All cohorts receive 7 consecutive days of dosing. Cohorts 6, 7: 8 subjects each (6 active, 2 placebo) Cohort 8: 14 subjects (12 active, 2 placebo)

干预措施: PSTB100 tablets (Drug)

A SAD study includes 5 predefined cohorts: Cohorts 1-5

Experimental

The Single Ascending Dose (SAD) study uses a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of a single oral dose of PSTB100 Tablets in healthy adult subjects under fasting conditions.

干预措施: PSTB100 tablets (Drug)

结局指标

主要结局

Time to Reach Maximum Observed Plasma concentration (Tmax)

时间窗: Part 1 : Pre- dose to 24 hours , 48 hours post dose, 72 hours post dose Part 2 : Pre- dose to 12 hours, and 24 hours post Day 1 dose to be collected within 15 minutes pre Day 2 dose

PK characteristics after single dose

Maximum Observed PSTB100 Plasma Concentration (Cmax)

时间窗: Part 1 : Pre- dose to 24 hours , 48 hours post dose, 72 hours post dose Part 2 : Pre- dose to 12 hours, and 24 hours post Day 1 dose to be collected within 15 minutes pre Day 2 dose

PK characteristics after single dose

PSTB100 area under the plasma concentration-time curve (AUC0-24h, AUC0-t, AUC0-∞, etc.)

时间窗: Part 1 : Pre- dose to 24 hours , 48 hours post dose, 72 hours post dose Part 2 : Pre- dose to 12 hours, and 24 hours post Day 1 dose to be collected within 15 minutes pre Day 2 dose

PK characteristics after single dose

Plasma clearance (CL/F)

时间窗: Part 1 : Pre- dose to 24 hours , 48 hours post dose, 72 hours post dose Part 2 : Pre- dose to 12 hours, and 24 hours post Day 1 dose to be collected within 15 minutes pre Day 2 dose

PK characteristics after single dose

Plasma elimination half-life (T₁/₂)

时间窗: Part 1 : Pre- dose to 24 hours , 48 hours post dose, 72 hours post dose Part 2 : Pre- dose to 12 hours, and 24 hours post Day 1 dose to be collected within 15 minutes pre Day 2 dose

PK characteristics after single dose

Mean residence time (MRT)

时间窗: Part 1 : Pre- dose to 24 hours , 48 hours post dose, 72 hours post dose Part 2 : Pre- dose to 12 hours, and 24 hours post Day 1 dose to be collected within 15 minutes pre Day 2 dose

PK characteristics after single dose

Steady-state time to peak (Tmax,ss)

时间窗: Pre- dose to 12 hours, 24 hours post day 1 dose, pre- day 4, pre- day 6， pre- day 7 to 24 hours post day 7 dose, 48 hours post day 7 dose.